You are here: Industry Insights > AC Immune

News List

AC Immune acquires Parkinson’s disease vaccine candidate pharmatimes
July 29, 2021
Swiss biopharma company AC Immune has announced its acquisition of a Parkinson’s disease vaccine candidate, developed by Affiris.
AC Immune and WuXi Biologics Expand Strategic Partnership contractpharma
November 11, 2020
Plan to accelerate AC Immune’s TDP-43 antibody into clinical development.
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug fiercebiotech
December 27, 2018
Eli Lilly has paid CHF 80 million ($81 million) upfront for the worldwide rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease.....
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership en-cphi.cn
December 20, 2018
WuXi Biologics and AC Immune SA announced the first steps of an exclusive strategic collaboration that covers biologics discovery, development and manufacturing.
Lilly teams up with AC Immune for Alzheimer’s drug pharmaceutical-technology
December 14, 2018
Eli Lilly has signed a licence and collaboration agreement with Swiss biotech AC Immune for the research and development of tau aggregation inhibitor small molecules.....
AC Immune, Lilly Announce License and Collaboration Agreement americanpharmaceuticalreview
December 13, 2018
AC Immune and Eli Lilly and Company announced the two companies have signed a license and collaboration agreement to research and develop.....
AC Immune finds new antibodies targeting neurodegenerative diseases pharmaceutical-technology
August 24, 2017
Swiss clinical stage biopharmaceutical company AC Immune has discovered new antibodies against two targets, Alpha-synuclein and TDP-43, in the pathogenesis of neurodegenerative diseases.